In the Claims

Please amend the claims pursuant to 37 C.F.R. §1.121 as indicated in the listing of claims which follows:

1. (Canceled)

2. (Currently amended) A compound ~~according to claim 1, which is~~ represented by the formula:

~~(Tyr-D-Ala-Gly-Phe-NH-)$_2$~~

(Tyr-D-Ser-Gly-Phe-NH-)$_2$

~~(Tyr-D-Thr-Gly-Phe-NH-)$_2$~~

(Tyr-D-Met-Gly-Phe-NH-)$_2$

(Tyr-D-Asn-Gly-Phe-NH-)$_2$

(Tyr-D-Leu-Gly-Phe-NH-)$_2$

(Tyr-D-Gln-Gly-Phe-NH-)$_2$

(Tyr-D-Ala-Gly-Trp-NH-)$_2$

(Tyr-D-Ser-Gly-Trp-NH-)$_2$

(Tyr-D-Thr-Gly-Trp-NH-)$_2$

(Tyr-D-Met-Gly-Trp-NH-)$_2$

(Tyr-D-Leu-Gly-Trp-NH-)$_2$

(Tyr-D-Gln-Gly-Trp-NH-)$_2$ or

(Tyr-D-Asn-Gly-Phe-NH-)$_2$.

3. (Currently amended) An analgesic medication containing the compound of claim ~~1~~ 2 and a pharmacologically acceptable carrier.

4. (Canceled)

5. (Previously presented) The analgesic medication according to claim 3, further comprising a compound selected from a group consisting of compounds blocking stimulatory amino acid receptors, compounds blocking tachykinin receptors, and compounds blocking cholecystokinin receptors.

6. (Previously presented) The analgesic medication according to claim 3, in the form of an aqueous physiological saline solution.

7. (Previously presented) The analgesic medication according to claim 3, characterised in that it is designed for direct application to the site of the desired analgesic activity.

8. (Previously presented) The analgesic medication according to claim 7, characterised in that it is designed for direct application to an appropriate site of the central nervous system.

9. (Previously presented) The analgesic medication according to claim 8, further comprising biphaline.

10. (Canceled)

11. (Currently amended) A method of alleviating pain in a subject, comprising administering to the subject at the site of the pain a compound according to claim ~~1~~ 2.

12. (Previously presented) The method according to claim 11, wherein the compound is administered directly to the appropriate site of the central nervous system.

13. (Previously presented) The method according to claim 11, further comprising administering biphaline.

14. (Previously presented) The method according to claim 11, further comprising administering a compound selected from the group consisting of compounds blocking stimulatory amino acid receptors, compounds blocking tachykinin receptors, and compounds blocking cholecystokinin receptors.

15. (Previously presented) The method according to claim 11, wherein the compound is administered constantly or periodically.

16. (Previously presented) The method according to claim 11, wherein the compound is in the form of a solution and it is administered by local infusion.